Publications by authors named "Paul Kirschmeier"

Claim this Profile
C
Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance.
Magda Bahcall, Cloud P Paweletz, Yanan Kuang, Luke J Taus, Taebo Sim, Paul T Kirschmeier

Mol Cancer Ther· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd.
Heidi M Haikala, Timothy Lopez, Jens Köhler, Pinar O Eser, Man Xu, Paul T Kirschmeier

Cancer Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations.
Atsuko Ogino, Jihyun Choi, Mika Lin, Margaret K Wilkens, Antonio Calles, Paul Kirschmeier

Mol Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade.
Kartik Sehgal, Andrew Portell, Elena V Ivanova, Patrick H Lizotte, Navin R Mahadevan, Paul T Kirschmeier

J Clin Invest· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma.
J Bryan Iorgulescu, Prafulla C Gokhale, Maria C Speranza, Benjamin K Eschle, Michael J Poitras, Paul T Kirschmeier

Clin Cancer Res· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway.
Kari J Kurppa, Yao Liu, Ciric To, Tinghu Zhang, Mengyang Fan, Paul T Kirschmeier

Cancer Cell· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
Kalindi Parmar, Bose S Kochupurakkal, Jean-Bernard Lazaro, Zhigang C Wang, Sangeetha Palakurthi, Paul T Kirschmeier

Clin Cancer Res· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity.
Sangeetha Palakurthi, Mari Kuraguchi, Sima J Zacharek, Enrique Zudaire, Wei Huang, Paul T Kirschmeier

Cancer Immunol Res· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Panagiotis A Konstantinopoulos, William T Barry, Michael Birrer, Shannon N Westin, Karen A Cadoo, Paul Kirschmeier

Lancet Oncol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity.
Juan J Miret, Paul Kirschmeier, Shohei Koyama, Mingrui Zhu, Yvonne Y Li

J Immunother Cancer· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer.
Shunsuke Kitajima, Elena Ivanova, Sujuan Guo, Ryohei Yoshida, Marco Campisi, Paul T Kirschmeier

Cancer Discov· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amplification of Wild-type Imparts Resistance to Crizotinib in Exon 14 Mutant Non-Small Cell Lung Cancer.
Magda Bahcall, Mark M Awad, Lynette M Sholl, Frederick H Wilson, Man Xu, Paul T Kirschmeier

Clin Cancer Res· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing.
Patrick H Lizotte, Ruey-Long Hong, Troy A Luster, Megan E Cavanaugh, Luke J Taus, Paul T Kirschmeier

Cancer Immunol Res· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13.
Mei Zeng, Nicholas P Kwiatkowski, Tinghu Zhang, Behnam Nabet, Mousheng Xu, Paul T Kirschmeier

Elife· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS.
Shunsuke Kitajima, Hajime Asahina, Ting Chen, Sujuan Guo, Laura Gutierrez Quiceno, Paul T Kirschmeier

Cancer Cell· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unraveling the clinicopathological features driving the emergence of mutations in metastatic breast cancer.
Yanan Kuang, Bilal Siddiqui, Jiani Hu, Matthew Pun, MacIntosh Cornwell, Paul Kirschmeier

NPJ Breast Cancer· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology.
Sobhana Babu Boga, Yongqi Deng, Liang Zhu, Yang Nan, Alan B Cooper, Paul Kirschmeier

ACS Med Chem Lett· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology.
Sobhana Babu Boga, Abdul-Basit Alhassan, Alan B Cooper, Ronald Doll, Neng-Yang Shih, Paul Kirschmeier

Bioorg Med Chem Lett· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.
Russell W Jenkins, Amir R Aref, Patrick H Lizotte, Elena Ivanova, Susanna Stinson, Paul T Kirschmeier

Cancer Discov· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.
Stergios J Moschos, Ryan J Sullivan, Wen-Jen Hwu, Ramesh K Ramanathan, Alex A Adjei, Paul Kirschmeier

JCI Insight· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recurrent ubiquitin B silencing in gynecological cancers establishes dependence on ubiquitin C.
Alexia T Kedves, Scott Gleim, Xiaoyou Liang, Dennis M Bonal, Frederic Sigoillot, Paul T Kirschmeier

J Clin Invest· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.
Monica M Mita, Alain C Mita, Jennifer L Moseley, Jennifer Poon, Karen A Small, Paul Kirschmeier

Br J Cancer· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics.
Joyce F Liu, Sangeetha Palakurthi, Qing Zeng, Shan Zhou, Elena Ivanova, Paul T Kirschmeier

Clin Cancer Res· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.
Cloud P Paweletz, Adrian G Sacher, Chris K Raymond, Ryan S Alden, Allison O'Connell, Paul Kirschmeier

Clin Cancer Res· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells.
Haymanti Bhanot, Mamatha M Reddy, Atsushi Nonami, Ellen L Weisberg, Dennis Bonal, Paul T Kirschmeier

Leukemia· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis